176 related articles for article (PubMed ID: 30638733)
1. Evaluation of a diagnostic
Lim CH; Seok HY; Hyun SH; Moon SH; Cho YS; Lee KH; Kim BT; Choi JY
Clin Radiol; 2019 Mar; 74(3):207-215. PubMed ID: 30638733
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
6. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of
Zhang Y; Han J; Li J; Cao J; Zhou Y; Deng S; Zhang B; Yang Y
J Cancer Res Clin Oncol; 2024 May; 150(5):265. PubMed ID: 38769201
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between
Yu P; Lei J; Xu B; Wang R; Shen Z; Tian J
Acad Radiol; 2020 May; 27(5):682-688. PubMed ID: 31311773
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
10. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
[TBL] [Abstract][Full Text] [Related]
12. The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions.
Sa R; Zhao HG; Dai YY; Guan F
Medicine (Baltimore); 2018 Sep; 97(38):e12521. PubMed ID: 30235771
[TBL] [Abstract][Full Text] [Related]
13. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
14. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
16. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
17. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
[TBL] [Abstract][Full Text] [Related]
20. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]